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ThermoﬂuorProtein misfolding is a hallmark of a number of metabolic diseases, in which fatty acid oxidation defects are
included. The latter result from genetic deﬁciencies in transport proteins and enzymes of the mitochondrial
β-oxidation, and milder disease conditions frequently result from conformational destabilization and de-
creased enzymatic function of the affected proteins. Small molecules which have the ability to raise the func-
tional levels of the affected protein above a certain disease threshold are thus valuable tools for effective drug
design. In this work we have investigated the effect of mitochondrial cofactors and metabolites as potential
stabilizers in two β-oxidation acyl-CoA dehydrogenases: short chain acyl-CoA dehydrogenase and the medi-
um chain acyl-CoA dehydrogenase as well as glutaryl-CoA dehydrogenase, which is involved in lysine and
tryptophan metabolism. We found that near physiological concentrations (low micromolar) of FAD resulted
in a spectacular enhancement of the thermal stabilities of these enzymes and prevented enzymatic activity
loss during a 1 h incubation at 40 °C. A clear effect of the respective substrate, which was additive to
that of the FAD effect, was also observed for short- and medium-chain acyl-CoA dehydrogenase but not for
glutaryl-CoA dehydrogenase. In conclusion, riboﬂavin may be beneﬁcial during feverish crises in patients
with short- and medium-chain acyl-CoA dehydrogenase as well as in glutaryl-CoA dehydrogenase deﬁcien-
cies, and treatment with substrate analogs to butyryl- and octanoyl-CoAs could theoretically enhance en-
zyme activity for some enzyme proteins with inherited folding difﬁculties., short chain acyl-CoA dehydro-
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Acyl-CoA dehydrogenases (ACDH) constitute a protein family that
in humans comprises 11 mitochondrial proteins. These proteins are
involved in fatty acid oxidation and amino acid metabolism and com-
prise the short (SCAD), medium (MCAD), long (LCAD) and very-long
(VLCAD) chain acyl-CoA dehydrogenases, ACAD9, ACAD10, ACAD11,
isovaleryl-CoA dehydrogenase (IVD), short/branched chain acyl-CoA
dehydrogenase (SBCAD), isobutyryl-CoA dehydrogenase (IBDH) and
glutaryl-CoA dehydrogenase (GCD). These enzymes all share high
sequence similarity, but differ in their substrate speciﬁcities. The elec-
trons gained in the respective dehydrogenation reactions by all
ACDH are transferred to the respiratory chain through electron trans-
fer ﬂavoprotein (ETF) and ETF:ubiquinone oxidoreductase (ETF:QO)[1–3]. These proteins share a common structural fold with two or
four subunits forming homodimers or homotetramers which invari-
ably harbor a FAD moiety as catalytic redox cofactor [4].
Genetic disorders in mitochondrial acyl-CoA dehydrogenases in-
volved in fatty acid oxidation (FAO) and amino acid metabolism
are among the most common metabolic disorders. For example,
MCAD deﬁciency is by far the most frequent disorder of this group
with a frequency of 1:15,000 in Caucasian populations [5–7]. New-
born screening for many of these disorders is currently performed
in many countries. Patients show a wide spectrum of symptoms,
which in many cases are triggered by metabolic stress (high ﬂux
through the respective pathway) or pathophysiological conditions
(e.g. fever), leading to further destabilization of mutant proteins
with residual enzyme activity. Treatment regimes aiming at ﬂux
reduction by avoiding respective metabolites and their precursors in
the diet have proved beneﬁcial [8–9]. As many disease associated
gene variations in the genes giving rise to variant proteins are of the
missense type [10–11] the pathogenesis is in many cases resulting
from defective folding [12]. As FAD has been shown to function
as a chaperone [13–14], treatment with riboﬂavin, the precursor of
FAD may theoretically increase the folding efﬁciency of mutant pro-
teins with residual activity [15–16]. However, although riboﬂavin
1659T.G. Lucas et al. / Biochimica et Biophysica Acta 1812 (2011) 1658–1663treatment has been sporadically tried in acyl-CoA dehydrogenase de-
ﬁciencies [8,17–19], no conclusive molecular studies addressing the
mechanistic and structural basis of these effects on the dehydroge-
nase enzymes have been performed.
In the current work we have investigated the effects of addition
of FAD, riboﬂavin or ACDH substrates and substrate analogs to study
in detail the effects of these compounds on the in vitro structural
stability of the two fatty acid oxidation ACDH, short-chain acyl-CoA
dehydrogenase (SCAD) and medium-chain acyl-CoA dehydrogenase
(MCAD) and on glutaryl-CoA dehydrogenase (GCD), which is
involved in amino acid metabolism. Our study can provide the basis
for evidence-based mechanistic treatment strategies as it establishes
the proof of principle for conformational and kinetic stabilization by
cofactor and substrates in these proteins. Thus, treatment with sub-
strate analogs to butyryl- and octanoyl-CoAs could theoretically
enhance enzyme activity for some enzymes with inherited folding
difﬁculties.
2. Materials and methods
2.1. Chemicals
All reagents were of the highest purity grade commercially
available. Fatty acid substrates, FAD and riboﬂavin were purchased
from Sigma. Isopropyl-β-D-thiogalactopyranoside (IPTG) was pur-
chased from VWR International.
2.2. ACDH expression and puriﬁcation
Plasmids with MCAD, SCAD or GCD cDNA lacking the sequence
encoding the mitochondrial transit peptide, and supplied with an N-
terminal ATG start codon and a C-terminal his-tag (6xhis+1xgln)
were constructed in the same arrangement in a pBluescriptKS(−)
(Stratagene) derived vector as described for the MCAD plasmid pWt
described [20]. Escherichia coli JM109 cells (Promega) were trans-
formed using standard procedures, and were grown in TB-medium
(12 g Bacto tryptone, 24 g yeast extract, 9.4 g dipotassium phosphate,
2.2 g monopotassium phosphate and 2 ml glycerol per liter) supple-
mented with 100 μg.ml−1 ampicillin at 30 °C in a shaking incubator
until OD532 of 0.5 was reached. The cells were then induced overnight
with 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) [21]. Cells
were harvested by centrifugation, resuspended in 10 mM hepes, 20%
ethylene glycol at pH 7.8, and 0.5 mM phenylmethylsulfonyl ﬂuoride
(PMSF) in the presence of DNase (PVL) and FAD, and disrupted in a
French press. The soluble fraction was subjected to a His-binding
resin, 5 ml His-Trap HP (GE Healthcare), equilibrated in 10 mM
hepes, 20% ethylene glycol, 200 mM NaCl, 10 mM imidazole and
0.5 mM PMSF at pH 7.8 (buffer A). The column was washed with
ﬁve volumes of buffer A, and bound proteins were eluted by a linear
gradient ranging from 10 to 500 mM imidazole, in buffer A. SCAD
eluted as pure proteins at ~220 mM imidazole and MCAD and GCD
eluted at ~160 mM imidazole. The purity of the pooled enzyme frac-
tions was conﬁrmed by SDS/PAGE. Pure fractions with 2.5 fold excess
FAD were fast-frozen using liquid nitrogen and stored at −80 °C.
2.3. Biochemical and enzymatic assays
UV/visible spectra and enzymatic activities were measured using a
Shimadzu UVPC-1601 spectrometer with cell stirring. Before each ex-
periment FAD excess added to buffers as a preservative was removed
by extensive washing using ultra ﬁltration/dilution. Protein concen-
tration was determined by the Bradford assay and FAD content was
measured by the absorbance at 450 nm. All experiments were per-
formed with pure proteins containing full occupancy of FAD site.
Final buffer for protein assays was 10 mM hepes pH 7.8. The acyl-
CoA dehydrogenase enzymatic activity was measured at 30 °Cmonitoring 2,6-dichlorophenolindophenol (DCPIP) reduction at
600 nm, in an assay with phenazine methosulfate and butyryl-CoA,
or octanoyl-CoA or glutaryl-CoA, respectively to SCAD, MCAD or
GCD [22].
2.4. Differential scanning ﬂuorimetry
Differential scanning ﬂuorimetry (DSF) was used to determine the
melting temperatures (Tm) of the proteins under different conditions.
This method is based on the use of the ﬂuorophore Sypro Orange
which becomes ﬂuorescent upon binding to hydrophobic protein
patches that get exposed upon thermal unfolding [23], being very use-
ful to determine protein stability in a variety of conditions [24]. Brieﬂy,
different buffers or compound solutionwas distributed into PCR plates
(Bio-Rad). Prior to measurements, protein solution (1.2 μM) with
Sypro Orange 5× (Invitrogen) was added to each well. The plates
were sealed with optical quality sealing tape (Bio-Rad) and run in an
iCycler iQ Real-Time PCR instrument (Bio-Rad) using excitation ﬁlter
from 530 to 560 nm and emission ﬁlter from 575 to 595. Temperature
range used was from 20 to 90 °C, with increments of 2 °C.min−1. Raw
data were exported to a spreadsheet, background corrected and the
thermal denaturation curves obtained from which the midpoint tran-
sitions (melting temperatures, Tm) have been determined for up to 96
different conditions in each assay. See Fig. S1 for a representative plot
of melting curves determined by DSF.
2.5. Functional studies under thermal stress
To study the effect of compounds on the biological activity of the
model enzymes, activity was measured after heat stress. Brieﬂy,
ACDHs (1.2 μM) were incubated for 1 h at 40 °C in the presence of
the selected compounds: substrates (20 μM) and/or FAD (20 μM).
Protein solution was added to the compound solution right before in-
cubation at 40 °C. Control samples in the absence of the compounds
were also prepared and treated in the same conditions. The enzy-
matic activity for each condition was determined immediately after
mixing (time 0) and then after 1 h of incubation as described in the
biochemical and enzymatic assay section. No protein precipitation
was observed.
3. Results
3.1. Effect of acyl-CoA substrates on ACDH stability under physiological
conditions
Cofactors, substrates and inhibitors are among small molecules
which are known to have the potential to exert a direct stabilizing
action over a protein fold by recovering misfolded conformations for
example via nucleation effects which restore native interactions
and/or promote the correct oligomeric state. Using differential scan-
ning ﬂuorescence (DSF) we have investigated in vitro the effect of di-
verse fatty acid substrates and related molecules on the stability of
three ACDH: glutaryl-CoA dehydrogenase (GCD), short chain acyl-
CoA dehydrogenase (SCAD) and the medium chain acyl-CoA dehy-
drogenase (MCAD). In order to mimic conditions such as those
found in mitochondria, we have used near physiological substrate
concentrations [25], which were always present in assays at low
micromolar concentrations (from 0.8 to 100 μM). With this approach,
we seek also to simulate conditions of mitochondrial ACDH dysfunc-
tion, in which substrate levels and metabolites are increased. For
the purpose, we have screened the effect of butyryl-CoA, octanoyl-
CoA, glutaryl-CoA, palmitoyl-CoA, acetyl-CoA and CoA, on the protein
thermal stabilities and the melting temperatures (Tm) were measured
at increasing concentrations (Fig. 1 and Supplemental Fig. S1,
Table S1). The results obtained showed that preferred substrates
(butyryl-CoA and octanoyl-CoA, respectively) of SCAD and MCAD
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Fig. 1. Dependence of substrate concentration on ACDH thermal stability. The thermal stabilities of SCAD and MCAD were determined by DSF in the presence of various compounds
and substrates at different concentrations: butyryl-CoA (□), octanoyl (○), glutaryl-CoA(△), palmitoyl-CoA (▽), acetyl-CoA (◁) and CoA (▷). Plots show relative protein stability
variations (ΔTm) compared to controls in which the midpoint of thermal unfolding has been determined in the absence of any added compound (Tm=50 °C for SCAD and
Tm=54 °C MCAD). Protein concentration was 1.2 μM and compound concentration varied between 0.16 and 100 μM, in 10 mM hepes pH 7.8. See Materials and methods for details
and supplementary materials for tables.
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stabilization (ΔTm≈+12 °C). Interestingly, this stabilization is
achieved even at very low concentrations and already at 20 μMmore
than 80% of themaximal stabilizing effect observed at higher substrate
concentrations (100 μM) is achieved. For these two proteins, although
the most signiﬁcant effect is limited to the preferred catalytic sub-
strate, some stabilization with lower magnitude (ΔTmb4 °C) is also
observed for the other molecules tested. However, substrate-induced
conformational stabilization does not seem to be a property shared
by acyl-CoA dehydrogenases in general, as we did not observe any ef-
fect of glutaryl-CoA on GCD (Table S1). These differences observed in
respect to substrate stabilization among ACDHs suggest that these
proteins, although sharing a common structural fold, can in fact have
their conformational properties modulated by distinct mechanisms,
a process which possibly relates to differences in protein dynamics
(discussed below). The substrate-induced stabilization effects ob-
served for SCAD and MCAD are thus suggestive of a stabilizing mech-
anism through which local effects resulting from substrate binding to
the active site are globally propagated to the protein.
3.2. FAD but not its precursor riboﬂavin stabilizes ACDH
We then set to investigate if FAD, the common ﬂavin cofactor pre-
sent in all acyl-CoA dehydrogenases, has also a stabilizing action over
the ACDH proteins. We had previously established that a slight excess
of FAD, similar to that found in patients undergoing riboﬂavin supple-
mentation therapy [26], has an important stabilizing effect over the
electron transfer ﬂavoprotein (ETF) under mild thermal stress mim-
icking a fever episode, even under conditions in which the protein co-
factor site is fully saturated [14]. We have now extended this analysis
to the three acyl-CoA dehydrogenases here studied, and for the pur-
pose the DSF assays of the different proteins (at 1.2 μM ﬁnal concen-
tration) were performed in the presence of a slight excess of FAD at
concentrations from 3 to 25 μM. Importantly, it should be noted that
the as puriﬁed proteins had already fully loaded ﬂavin binding sites
(N0.9 FAD/mol). The results obtained show that FAD has a stabilizing
effect on SCAD, MCAD and GCD, resulting in considerable increases of
the Tm (Fig. 2, Table S2). In order to investigate if this stabilization is
speciﬁc for FAD or if, on the other hand, isoalloxazine-ring mediated
interactions could promote an identical effect, we have carried outexperiments using riboﬂavin. In these cases, no stabilization was ob-
served thus showing that at the concentrations and conditions tested,
the stabilization is not afforded generically by any ﬂavin moiety, but
rather it is speciﬁc for FAD.
3.3. The combination of cofactor and substrate stabilization is nearly
additive
Having established that mitochondrial cofactors and metabolites
are potential stabilizers of native β-oxidation ﬂavoprotein dehydro-
genases, we have investigated for possible synergistic effects. For
the purpose, we have analyzed SCAD without FAD added in parallel
with assays in which a moderate excess of FAD (20 μM) was included
in the assay solution; for all these conditions the additional effects of
substrates were analyzed (Fig. 3, Table S3). The results obtained show
that i) the tested combinations of compounds stabilize SCAD; and
ii) the stabilization achieved is nearly additive in respect to that ob-
served in experiments in which the effect of the molecules has been
tested individually (Fig. 3). This observation agrees with the results
described in the previous sections of this study as it conﬁrms that
substrates and the cofactor result in protein stabilization via different
mechanisms: the former by binding to the active site pocket, and the
latter by shifting the dissociation equilibrium of the redox cofactor to-
ward the protein bound state. What is very interesting to note is that
the combination of butyryl-CoA and FAD increases substantially
the melting temperature of SCAD. This illustrates how the confor-
mation of an ACDH can be effectively rescued by small molecule
ligands, in this case natural mitochondrial metabolites at very low
concentrations.
3.4. Cofactors and metabolites prevent activity loss during mild
temperature stress
In order to be truly effective, protein stabilization by small mole-
cules must not compromise the biological activity. In some cases, a
substantial increase in the protein melting temperature corresponds
to a rigidiﬁcation of the protein structure leading to decreased dy-
namics and ﬂexibility, thus compromising biological activity [27].
An adequate stability–activity balance must thus be attained so that
a better protein conformation is not obtained at the expense of a
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Fig. 2. Effect of FAD and riboﬂavin on ACDH thermal stability. The effect of FAD and riboﬂavin at different concentrations on the thermal stabilities of SCAD, MCAD and GCD (1.2 μM)
was determined at various ﬂavin concentrations (3.1 to 25 μM) in 10 mM hepes pH 7.8. Proteins were added to ﬂavin solutions right before the analysis. Bars denote protein sta-
bility variations (ΔTm) in respect to controls. Please note that the x-axis is not crossing at y=0. See Materials and methods for details and supplementary materials for tables.
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ity we have carried out experiments in which GCD, MCAD and SCAD
were incubated for 1 h at 40 °C with and without FAD, in combination
with butyryl-CoA, octanoyl-CoA and glutaryl-CoA. After this period,
which simulates a mild temperature stress resembling a fever epi-
sode, the remaining enzymatic activity was measured. The results
obtained in control experiments without added molecules show
that these are rather destabilizing conditions as after this incubation
the enzymes had low residual activities: 48% for GCD, 31% for MCAD
and 49% for SCAD (Fig. 4, Table S4). For all cases, this activity decay
was prevented if FAD was present at low concentrations (20 μM) dur-
ing the thermal stress. Likewise, the preferred substrates (octanoyl-
CoA for MCAD and butyryl-CoA for SCAD) also prevent activity loss
and, when in combination with the ﬂavin cofactor, an enzymatic acti-
vation is observed. These results are in agreement with the increased
melting temperatures and show that the conformational stabilization
does not sacriﬁce catalytic activity. In this respect, it is interesting
to note that non-optimal substrates withheld activity during the tem-
perature stress assay at 40 °C. This is for example the case of butyryl-
CoA for MCAD: at 20 μM it yields a modest increase in the meltingFA
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Fig. 3. Combined effect of FAD and metabolites on SCAD stability. The thermal stabili-
ties of SCAD (1.2 μM) in the presence of CoA, acetyl-CoA, butyryl-CoA, octanoyl-CoA,
glutaryl-CoA or palmitoyl-CoA (20 μM) were determined in the presence and absence
of FAD (20 μM). Protein was added to ﬂavin and metabolite solutions right before
the analysis. Bars denote protein stability variations (ΔTm) in respect to controls. See
Materials and methods for details and supplementary materials for tables.temperature (ΔTm≈+2 °C), but under identical conditions it pre-
vents activity loss during 1 h incubation at 40 °C, affording a residual
activity of 70% (versus 30% in its absence). On the other hand, glu-
taryl-CoA, which is not a substrate for either SCAD or MCAD has no
preventive effect.
4. Discussion
In this study we have investigated the effect of mitochondrial cofac-
tors and metabolites as potential stabilizers in three acyl-CoA dehydro-
genases: GCD, SCAD and MCAD. The rationale for the study was based
on the principle that ligands and substrates that increase protein stabil-
ity and function could in theory be used as small molecule pharmaco-
logical chaperones, restoring levels of the affected proteins above
critical disease thresholds in the associated metabolic pathologies. We
have tested the hypothesis that metabolites and cofactors at micromo-
lar physiological concentrations could play this role, and we have un-
dertaken two complementary approaches: on the one hand testing
effects on protein stabilization, and, on the other, testing effects on the
protein kinetic stability upon an in vitro fever simulation.
Our results show that for MCAD and SCAD, the preferred sub-
strates and the FAD cofactor have a dramatic stabilizing effect, in-
creasing the protein thermal stability and preventing activity loss
during a mild temperature stress. Interestingly, GCD substrate bind-
ing does not seem to be coupled with overall fold stabilization,
whereas the FAD cofactor clearly does. This suggests that substrate-
binding in GCD may result in a somehow different set of conforma-
tional changes that do not yield effective stabilization as observed in
MCAD and SCAD, which reﬂects differences among the dynamic prop-
erties of these enzymes. In the case of SCAD, cofactor and substrate
synergistically restore stability and catalytic activity. Thus, these re-
sults clearly establish the proof of principle that cofactors and metab-
olites at physiological levels are potential stabilizers of mitochondrial
acyl-CoA dehydrogenases. The fact that these substantial effects take
place at near physiological concentrations of the compounds, which
have the same magnitude as the Km for the most effective enzyme–
substrate pairs, strongly suggests that the maintenance of a high ac-
tive site occupancy is an effective stabilizing strategy for SCAD and
MCAD. Interesting to note is the fact that in the case of SCAD patients
there is accumulation of butyryl-CoA byproducts such as ethylmalo-
nic acid (EMA) in the cells, blood and urine [28-30]. Therefore, pa-
tients could potentially beneﬁt of a treatment that would increase
the intra-mitochondrial level of butyryl-CoA or by a substrate analog
which would have the ability to stabilize the enzyme. The
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would be overcome by the fact that its binding would increase pro-
tein stabilization and result in a higher level of correctly folded pro-
tein in the mitochondria with extended lifetime, thus surpassing a
certain functional threshold below which there is dysfunction and
disease. Thus developing such substrate analog compounds would
be potentially beneﬁcial to patients. In fact the same role could be
played by inhibitors, such as in the case of those that have been devel-
oped and are used therapeutically to treat for example lysosomal dis-
orders, such as Gaucher disease. In the latter case, inhibitor molecules
bind to folding variants of the affected glucocerebrosidase enzyme,
increasing their thermodynamic and kinetic stability, thus favoring
their correct trafﬁcking and an increase of enzymatic function above
a critical disease threshold [31–32]. Other relevant modes of pharma-
cological rescue of metabolic disorders focus on increasing protein
expression levels, which could also be a possibility in respect to in-
creasing the levels of enzyme, even if partially catalytically impaired.
As an example, bezaﬁbrate was shown to induce both mRNA and pro-
tein expression levels of VLCAD and CPTII in deﬁcient ﬁbroblast [33],
and has also proved to be effective in patients [34].
In the present case, the highly stabilizing effect of FAD is sugges-
tive of a direct effect in the proteins, which corroborates the view
that dietary administration of high doses of the riboﬂavin precursor
results in an intracellular increase in FAD levels [26] is in fact poten-
tially beneﬁcial for patients suffering from inherited acyl-CoA
dehydrogenase deﬁciencies. Although comprehensive studies on the
clinical effects of high-dose riboﬂavin treatments are scarce, data
from a subgroup of patients with SCAD deﬁciency is not conclusive
in respect to establishing a clear relationship between high-dose ribo-
ﬂavin treatments and clinical improvements, therefore broader and
more complete studies are needed [18]. Nevertheless, the biochemi-
cal improvements resulting from increased FAD levels, as a result of
vitamin therapy are well established, and point to a pivotal role for
this cofactor. Even low FAD:protein ratios substantially improve pro-
tein stability and sustain enzymatic activity, and presumably the
same effect takes place in disease-associated variants. One could
speculate if whether FAD could be a general regulator of β-oxidation.
Under this hypothetical scenario, increased steady-state levels of β-
oxidation enzymes could be induced by high FAD concentrations,
both as a result of a direct stimulatory effect of FAD over translation[35] and also by signiﬁcant increase in protein stability promoted by
FAD, that would inhibit protease-mediated protein degradation.
Future experiments will contribute to clarify this hypothesis.
The data here collected suggests that cofactor dissociation during
thermal stress may be compensated by exogenous FAD, which can
be provided by riboﬂavin treatment [26]. The relevance of our obser-
vations is that a very signiﬁcant stabilization is achieved at FAD con-
centrations (20 μM) which are within the physiological cellular range
[25]. This stabilization effect arises probably from a shift in the equi-
librium between bound and unbound cofactors, in the direction that
favors the bound form resulting in an improvement of the stability
of the protein. Important to note is that in our experiments the initial
proteins had 95% occupancy of the ﬂavin binding site; therefore, FAD
is stabilizing the holo form of the protein, in contrast with the well
described stabilization of apo forms by respective cofactors. Mecha-
nistically, the effect of FAD might be interpreted in respect to the
principle of ligand-based kinetic stabilization; the availability of the
FAD cofactor results in an equilibrium shift toward the bound state,
further promoted by the fact that binding of a molecule to the active
pocket contributes to the kinetic stability of the protein conformation,
which further increases the end-point residual activity.
With this study we provide a quantitative measure for the FAD-
dependent stability of mitochondrial acyl-CoA dehydrogenases,
through saturation of the ﬂavin binding site yielding conformational
and structural stabilization, therefore providing a framework that ex-
plains the fact that mature acyl-CoA dehydrogenases undergo fast
degradation under ﬂavin-depletion [35]. Therefore, riboﬂavin may
be beneﬁcial during feverish crises in patients with the short- and
the medium-chain acyl-CoA dehydrogenase as well as in glutaryl-
CoA dehydrogenase deﬁciencies, and treatment with substrate ana-
logs to butyryl- and octanoyl-CoAs could theoretically enhance en-
zyme activity for some enzyme proteins with inherited folding
difﬁculties. Future research will contribute to clarify this possibility.
Acknowledgements
The work was supported by funds from the Fundação para a
Ciência e Tecnologia (FCT/MCTES, Portugal) via research grant
PTDC/SAU-GMG/70033/2006 (to C. M. G) and by CLIMB UK — Children
living with metabolic disease (to C. M. G.). The Fundação para a
1663T.G. Lucas et al. / Biochimica et Biophysica Acta 1812 (2011) 1658–1663Ciência e Tecnologia (FCT/MCTES, Portugal) is acknowledged for fel-
lowships BII — Bolsa de Iniciação à Investigação (to T. G. L.),
SFRH/BPD/74475/2010 (to B. J. H.) and SFRH/BPD/34763/2007 (to
J.V.R). The Alfred Benzon Foundation is acknowledged for an inter-
change grant.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.bbadis.2011.09.009.
References
[1] D.L. Roberts, F.E. Frerman, J.J. Kim, Three-dimensional structure of human elec-
tron transfer ﬂavoprotein to 2.1-A resolution, Proc. Natl. Acad. Sci. U.S.A. 93
(1996) 14355–14360.
[2] J. Zhang, F.E. Frerman, J.J. Kim, Structure of electron transfer ﬂavoprotein-ubiqui-
none oxidoreductase and electron transfer to the mitochondrial ubiquinone pool,
Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 16212–16217.
[3] S. Ghisla, C. Thorpe, Acyl-CoA dehydrogenases. A mechanistic overview, Eur. J.
Biochem. 271 (2004) 494–508.
[4] J.J. Kim, R. Miura, Acyl-CoA dehydrogenases and acyl-CoA oxidases. Structural basis
for mechanistic similarities and differences, Eur. J. Biochem. 271 (2004) 483–493.
[5] G.F. Hoffmann, R. von Kries, D. Klose, M. Lindner, A. Schulze, A.C. Muntau, W.
Roschinger, B. Liebl, E. Mayatepek, A.A. Roscher, Frequencies of inherited organic
acidurias and disorders of mitochondrial fatty acid transport and oxidation in
Germany, Eur. J. Pediatr. 163 (2004) 76–80.
[6] E.M. Maier, B. Liebl, W. Roschinger, U. Nennstiel-Ratzel, R. Fingerhut, B. Olgemol-
ler, U. Busch, N. Krone, R. v Kries, A.A. Roscher, Population spectrum of ACADM
genotypes correlated to biochemical phenotypes in newborn screening for medi-
um-chain acyl-CoA dehydrogenase deﬁciency, Hum. Mutat. 25 (2005) 443–452.
[7] B.S. Andresen, S.F. Dobrowolski, L. O'Reilly, J. Muenzer, S.E. McCandless, D.M.
Frazier, S. Udvari, P. Bross, I. Knudsen, R. Banas, D.H. Chace, P. Engel, E.W. Naylor,
N. Gregersen, Medium-chain acyl-CoA dehydrogenase (MCAD) mutations iden-
tiﬁed by MS/MS-based prospective screening of newborns differ from those
observed in patients with clinical symptoms: identiﬁcation and characterization
of a new, prevalent mutation that results in mild MCAD deﬁciency, Am. J. Hum.
Genet. 68 (2001) 1408–1418.
[8] S. Kolker, E. Christensen, J.V. Leonard, C.R. Greenberg, A. Boneh, A.B. Burlina, A.P.
Burlina, M. Dixon, M. Duran, A. Garcia Cazorla, S.I. Goodman, D.M. Koeller, M.
Kyllerman, C. Muhlhausen, E. Muller, J.G. Okun, B. Wilcken, G.F. Hoffmann, P.
Burgard, Diagnosis and management of glutaric aciduria type I — revised recom-
mendations, J. Inherit. Metab. Dis. 34 (2011) 677–694.
[9] R.S. Rector, J.A. Ibdah, Fatty acid oxidation disorders: maternal health and neona-
tal outcomes, Semin. Fetal Neonatal Med. 15 (2010) 122–128.
[10] B. Keyser, C. Muhlhausen, A. Dickmanns, E. Christensen, N. Muschol, K. Ullrich, T.
Braulke, Disease-causing missense mutations affect enzymatic activity, stability
and oligomerization of glutaryl-CoA dehydrogenase (GCDH), Hum. Mol. Genet.
17 (2008) 3854–3863.
[11] N. Gregersen, B.S. Andresen, C.B. Pedersen, R.K. Olsen, T.J. Corydon, P. Bross, Mito-
chondrial fatty acid oxidation defects—remaining challenges, J. Inherit. Metab.
Dis. 31 (2008) 643–657.
[12] N. Gregersen, P. Bross, S. Vang, J.H. Christensen, Protein misfolding and human
disease, Annu. Rev. Genomics Hum. Genet. 7 (2006) 103–124.
[13] T. Saijo, K. Tanaka, Isoalloxazine ring of FAD is required for the formation of the
core in the Hsp60-assisted folding of medium chain acyl-CoA dehydrogenase sub-
unit into the assembly competent conformation in mitochondria, J. Biol. Chem.
270 (1995) 1899–1907.
[14] B.J. Henriques, J.V. Rodrigues, R.K. Olsen, P. Bross, C.M. Gomes, Role ofﬂavinylation in a
mild variant of multiple acyl-CoA dehydrogenation deﬁciency: a molecular rationale
for the effects of riboﬂavin supplementation, J. Biol. Chem. 284 (2009) 4222–4229.
[15] P. Leandro, C.M. Gomes, Protein misfolding in conformational disorders: rescue
of folding defects and chemical chaperoning,Mini Rev.Med. Chem. 8 (2008) 901–911.
[16] B.J. Henriques, R.K. Olsen, P. Bross, C.M. Gomes, Emerging roles for riboﬂavin in
functional rescue of mitochondrial beta-oxidation ﬂavoenzymes, Curr. Med.
Chem. 17 (2010) 3842–3854.[17] M. Duran, C.B.J.M. Cleutjens, D. Ketting, L. Dorland, J.B.C. Deklerk, F.J. Vansprang,
R. Berger, Diagnosis of medium-chain acyl-Coa dehydrogenase-deﬁciency in lym-
phocytes and liver by a gas-chromatographic method — the effect of oral riboﬂa-
vin supplementation, Pediatr. Res. 31 (1992) 39–42.
[18] B.T. van Maldegem, M. Duran, R.J.A. Wanders, H.R. Waterham, F.A. Wijburg,
Flavin adenine dinucleotide status and the effects of high-dose riboﬂavin
treatment in short-chain acyl-CoA dehydrogenase deﬁciency, Pediatr. Res. 67
(2010) 304–308.
[19] N.J. Brandt, N. Gregersen, E. Christensen, I.H. Gron, K. Rasmussen, Treatment of
glutaryl-CoA dehydrogenase deﬁciency (glutaric aciduria). Experience with diet,
riboﬂavin, and GABA analogue, J. Pediatr. 94 (1979) 669–673.
[20] P. Bross, C. Jespersen, T.G. Jensen, B.S. Andresen, M.J. Kristensen, V.Winter, A. Nandy,
F. Krautle, S. Ghisla, L. Bolundi, J.J. Kim, N. Gregersen, Effects of two mutations
detected in medium chain acyl-CoA dehydrogenase (MCAD)-deﬁcient patients on
folding, oligomer assembly, and stability of MCAD enzyme, J. Biol. Chem. 270
(1995) 10284–10290.
[21] T.V. Nguyen, C. Riggs, D. Babovic-Vuksanovic, Y.S. Kim, J.F. Carpenter, T.P. Burghardt,
N. Gregersen, J. Vockley, Puriﬁcation and characterization of two polymorphic vari-
ants of short chain acyl-CoA dehydrogenase reveal reduction of catalytic activity and
stability of the Gly185Ser enzyme, Biochemistry 41 (2002) 11126–11133.
[22] C. Thorpe, R.G. Matthews, C.H. Williams, Jr., Acyl-coenzyme A dehydrogenase
from pig kidney, Puriﬁcation and properties, Biochemistry 18 (1979) 331–337.
[23] F.H. Niesen, H. Berglund, M. Vedadi, The use of differential scanning ﬂuorimetry
to detect ligand interactions that promote protein stability, Nat. Protoc. 2
(2007) 2212–2221.
[24] J.V. Rodrigues, V. Prosinecki, I. Marrucho, L.P. Rebelo, C.M. Gomes, Protein stability
in an ionic liquid milieu: on the use of differential scanning ﬂuorimetry, Phys.
Chem. Chem. Phys. 13 (2011) 13614–13616.
[25] B.D. Bennett, E.H. Kimball, M. Gao, R. Osterhout, S.J. Van Dien, J.D. Rabinowitz, Abso-
lutemetabolite concentrations and implied enzyme active site occupancy in Escher-
ichia coli, Nat. Chem. Biol. 5 (2009) 593–599.
[26] E. Gianazza, L. Vergani, R. Wait, C. Brizio, D. Brambilla, S. Begum, T.A. Giancaspero,
F. Conserva, I. Eberini, D. Bufano, C. Angelini, E. Pegoraro, A. Tramontano, M. Bar-
ile, Coordinated and reversible reduction of enzymes involved in terminal oxida-
tive metabolism in skeletal muscle mitochondria from a riboﬂavin-responsive,
multiple acyl-CoA dehydrogenase deﬁciency patient, Electrophoresis 27 (2006)
1182–1198.
[27] A.R. Correia, T. Wang, E.A. Craig, C.M. Gomes, Iron-binding activity in yeast fra-
taxin entails a trade off with stability in the alpha1/beta1 acidic ridge region, Bio-
chem. J. 426 (2010) 197–203.
[28] N. Gregersen, V.S.Winter,M.J. Corydon, T.J. Corydon, P. Rinaldo, A. Ribes, G.Martinez,
M.J. Bennett, C. Vianey-Saban, A. Bhala, D.E. Hale, W. Lehnert, S. Kmoch, M. Roig, E.
Riudor, H. Eiberg, B.S. Andresen, P. Bross, L.A. Bolund, S. Kolvraa, Identiﬁcation of
four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in
two patients: one of the variant alleles, 511C–NT, is present at an unexpectedly
high frequency in the general population, as was the case for 625G–NA, together
conferring susceptibility to ethylmalonic aciduria, Hum. Mol. Genet. 7 (1998)
619–627.
[29] C.B. Pedersen, Z. Zolkipli, S. Vang, J. Palmfeldt, M. Kjeldsen, V. Stenbroen, S.P.
Schmidt, R.J. Wanders, J.P. Ruiter, F. Wibrand, I. Tein, N. Gregersen, Antioxidant
dysfunction: potential risk for neurotoxicity in ethylmalonic aciduria, J. Inherit.
Metab. Dis. 33 (2010) 211–222.
[30] R. Jethva, M.J. Bennett, J. Vockley, Short-chain acyl-coenzyme A dehydrogenase
deﬁciency, Mol. Genet. Metab. 95 (2008) 195–200.
[31] W. Zheng, J. Padia, D.J. Urban, A. Jadhav, O. Goker-Alpan, A. Simeonov, E. Goldin,
D. Auld, M.E. LaMarca, J. Inglese, C.P. Austin, E. Sidransky, Three classes of gluco-
cerebrosidase inhibitors identiﬁed by quantitative high-throughput screening are
chaperone leads for Gaucher disease, Proc. Natl. Acad. Sci. U.S.A. 104 (2007)
13192–13197.
[32] Z. Yu, A.R. Sawkar, J.W. Kelly, Pharmacologic chaperoning as a strategy to treat
Gaucher disease, FEBS J. 274 (2007) 4944–4950.
[33] F. Djouadi, F. Aubey, D. Schlemmer, J.P. Ruiter, R.J. Wanders, A.W. Strauss, J. Bastin,
Bezaﬁbrate increases very-long-chain acyl-CoA dehydrogenase protein and
mRNA expression in deﬁcient ﬁbroblasts and is a potential therapy for fatty
acid oxidation disorders, Hum. Mol. Genet. 14 (2005) 2695–2703.
[34] J.P. Bonnefont, J. Bastin, A. Behin, F. Djouadi, Bezaﬁbrate for an inborn mitochon-
drial beta-oxidation defect, N. Engl. J. Med. 360 (2009) 838–840.
[35] M. Nagao, K. Tanaka, FAD-dependent regulation of transcription, translation,
post-translational processing, and post-processing stability of various mitochon-
drial acyl-CoA dehydrogenases and of electron transfer ﬂavoprotein and the site
of holoenzyme formation, J. Biol. Chem. 267 (1992) 17925–17932.
